Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

102
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
102
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

149
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
149
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Ligand Binding Sites02:40

Ligand Binding Sites

12.7K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-Guided Grafting of Cell-Penetrating Motifs into Stapled Peptides for Intracellular PPI Inhibition.

Journal of medicinal chemistry·2026
Same author

Complementary Quantitation of Inorganic Counterions and Organic Components Using ICP OES and qNMR for Organo-Sulfonic Salts.

ACS omega·2026
Same author

Correction to "Linker and Conjugation Site Synergy in Antibody-Drug Conjugates: Impacts on Biological Activity".

Bioconjugate chemistry·2026
Same author

An Anti-Cell Adhesion Molecule 1 Antibody Improves Mite Antigen-Induced Atopic Dermatitis-Like Lesions and Pruritus in NC/Nga Mice.

Medical principles and practice : international journal of the Kuwait University, Health Science Centre·2026
Same author

Metformin suppresses β-cell apoptosis under ER stress by inhibiting protein translation.

Metabolism: clinical and experimental·2026
Same author

Glycolytic metabolism of CD8<sup>+</sup> T-cells affects susceptibility to human leukocyte antigen-mediated abacavir-induced hypersensitivity.

British journal of pharmacology·2026

Related Experiment Video

Updated: May 27, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K

Clozapine as an E3 Ligand for PROTAC Technology.

Reina Takano1,2, Nobumichi Ohoka3, Takashi Kurohara2

  • 1Graduate School of Medical Life Science, Yokohama City University, Kanagawa 210-9501, Japan.

ACS Medicinal Chemistry Letters
|February 19, 2025
PubMed
Summary

Researchers developed novel proteolysis-targeting chimeras (PROTACs) using clozapine as an E3 ligand. This approach successfully degraded target proteins, including the cancer-related estrogen receptor alpha, advancing drug discovery.

More Related Videos

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.2K
Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

12.7K

Related Experiment Videos

Last Updated: May 27, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.2K
Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

12.7K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Proteolysis-targeting chimeras (PROTACs) are an emerging therapeutic modality.
  • Development of novel ubiquitin ligase (E3) ligands is critical for PROTAC technology.
  • Identifying new E3 ligands expands the scope of targetable proteins for degradation.

Purpose of the Study:

  • To investigate the antipsychotic drug clozapine as a novel E3 ligand for PROTAC development.
  • To synthesize and evaluate clozapine-based PROTACs for protein degradation.
  • To explore the potential of clozapine-based PROTACs in cancer therapy.

Main Methods:

  • Synthesis of clozapine-based PROTACs, including Halo-PEG-Clozapine and Tamoxifen-PEG-Clozapine.
  • Cell-based assays to assess the degradation of target proteins (HaloTag and estrogen receptor alpha).
  • Utilized inhibitors and small interfering RNAs (siRNAs) to elucidate the degradation pathway.

Main Results:

  • A clozapine PROTAC successfully induced degradation of a model HaloTag-fused protein.
  • Tamoxifen-PEG-Clozapine demonstrated degradation of estrogen receptor alpha in MCF-7 breast cancer cells.
  • Degradation of estrogen receptor alpha was confirmed to occur via the ubiquitin-proteasome system involving E3 ligase N-recognin 5.

Conclusions:

  • Clozapine serves as a viable and promising E3 ligand for PROTAC design.
  • The use of clozapine expands the molecular toolkit for creating novel PROTACs.
  • This research contributes to advancing drug discovery by enabling targeted protein degradation for disease treatment.